Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

LY4584180

Small molecule (Molecular glue degrader) · Degrader of B-cell lymphoma 6 protein (BCL6) · developed by ELI LILLY &

Phase 1 Most advanced trial
LLY Developer

What is LY4584180?

LY4584180 is an orally bioavailable molecular glue that binds the transcriptional repressor BCL6, inducing BCL6 dimers to form polymers that are marked for ubiquitination and proteasomal degradation. It is being studied in non-Hodgkin lymphoma, diffuse large B-cell lymphoma and follicular lymphoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule (Molecular glue degrader)
Targets
B-cell lymphoma 6 protein (BCL6)
Mechanism
Degrader of B-cell lymphoma 6 protein (BCL6)
Pathways
E3 ligase ubiquitination, proteasome-mediated degradation, re-expression of BCL6-repressed genes
Therapy area
Oncology
Developer
ELI LILLY & (LLY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

Conditions studied

Follicular LymphomaLymphoma, Diffuse Large B-CellLymphoma, Non-Hodgkin's

Other drugs acting on BCL6

More from ELI LILLY &

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the LLY page.

Follow LLY, the company behind LY4584180

See LLY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LLY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.